293 related articles for article (PubMed ID: 28104789)
1. A novel humanized mouse model of Huntington disease for preclinical development of therapeutics targeting mutant huntingtin alleles.
Southwell AL; Skotte NH; Villanueva EB; Østergaard ME; Gu X; Kordasiewicz HB; Kay C; Cheung D; Xie Y; Waltl S; Dal Cengio L; Findlay-Black H; Doty CN; Petoukhov E; Iworima D; Slama R; Ooi J; Pouladi MA; Yang XW; Swayze EE; Seth PP; Hayden MR
Hum Mol Genet; 2017 Mar; 26(6):1115-1132. PubMed ID: 28104789
[TBL] [Abstract][Full Text] [Related]
2. An enhanced Q175 knock-in mouse model of Huntington disease with higher mutant huntingtin levels and accelerated disease phenotypes.
Southwell AL; Smith-Dijak A; Kay C; Sepers M; Villanueva EB; Parsons MP; Xie Y; Anderson L; Felczak B; Waltl S; Ko S; Cheung D; Dal Cengio L; Slama R; Petoukhov E; Raymond LA; Hayden MR
Hum Mol Genet; 2016 Sep; 25(17):3654-3675. PubMed ID: 27378694
[TBL] [Abstract][Full Text] [Related]
3. A fully humanized transgenic mouse model of Huntington disease.
Southwell AL; Warby SC; Carroll JB; Doty CN; Skotte NH; Zhang W; Villanueva EB; Kovalik V; Xie Y; Pouladi MA; Collins JA; Yang XW; Franciosi S; Hayden MR
Hum Mol Genet; 2013 Jan; 22(1):18-34. PubMed ID: 23001568
[TBL] [Abstract][Full Text] [Related]
4. Potent and sustained huntingtin lowering via AAV5 encoding miRNA preserves striatal volume and cognitive function in a humanized mouse model of Huntington disease.
Caron NS; Southwell AL; Brouwers CC; Cengio LD; Xie Y; Black HF; Anderson LM; Ko S; Zhu X; van Deventer SJ; Evers MM; Konstantinova P; Hayden MR
Nucleic Acids Res; 2020 Jan; 48(1):36-54. PubMed ID: 31745548
[TBL] [Abstract][Full Text] [Related]
5. Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease.
Van Raamsdonk JM; Murphy Z; Slow EJ; Leavitt BR; Hayden MR
Hum Mol Genet; 2005 Dec; 14(24):3823-35. PubMed ID: 16278236
[TBL] [Abstract][Full Text] [Related]
6. Wild-type huntingtin ameliorates striatal neuronal atrophy but does not prevent other abnormalities in the YAC128 mouse model of Huntington disease.
Van Raamsdonk JM; Pearson J; Murphy Z; Hayden MR; Leavitt BR
BMC Neurosci; 2006 Dec; 7():80. PubMed ID: 17147801
[TBL] [Abstract][Full Text] [Related]
7. Translation of MicroRNA-Based Huntingtin-Lowering Therapies from Preclinical Studies to the Clinic.
Miniarikova J; Evers MM; Konstantinova P
Mol Ther; 2018 Apr; 26(4):947-962. PubMed ID: 29503201
[TBL] [Abstract][Full Text] [Related]
8. Progressive phenotype and nuclear accumulation of an amino-terminal cleavage fragment in a transgenic mouse model with inducible expression of full-length mutant huntingtin.
Tanaka Y; Igarashi S; Nakamura M; Gafni J; Torcassi C; Schilling G; Crippen D; Wood JD; Sawa A; Jenkins NA; Copeland NG; Borchelt DR; Ross CA; Ellerby LM
Neurobiol Dis; 2006 Feb; 21(2):381-91. PubMed ID: 16150600
[TBL] [Abstract][Full Text] [Related]
9. Striatal synaptic dysfunction and hippocampal plasticity deficits in the Hu97/18 mouse model of Huntington disease.
Kolodziejczyk K; Parsons MP; Southwell AL; Hayden MR; Raymond LA
PLoS One; 2014; 9(4):e94562. PubMed ID: 24728353
[TBL] [Abstract][Full Text] [Related]
10. Phenotype onset in Huntington's disease knock-in mice is correlated with the incomplete splicing of the mutant huntingtin gene.
Franich NR; Hickey MA; Zhu C; Osborne GF; Ali N; Chu T; Bove NH; Lemesre V; Lerner RP; Zeitlin SO; Howland D; Neueder A; Landles C; Bates GP; Chesselet MF
J Neurosci Res; 2019 Dec; 97(12):1590-1605. PubMed ID: 31282030
[TBL] [Abstract][Full Text] [Related]
11. Effects of mutant huntingtin inactivation on Huntington disease-related behaviours in the BACHD mouse model.
Cheong RY; Baldo B; Sajjad MU; Kirik D; Petersén Å
Neuropathol Appl Neurobiol; 2021 Jun; 47(4):564-578. PubMed ID: 33330988
[TBL] [Abstract][Full Text] [Related]
12. A Comprehensive Haplotype-Targeting Strategy for Allele-Specific HTT Suppression in Huntington Disease.
Kay C; Collins JA; Caron NS; Agostinho LA; Findlay-Black H; Casal L; Sumathipala D; Dissanayake VHW; Cornejo-Olivas M; Baine F; Krause A; Greenberg JL; Paiva CLA; Squitieri F; Hayden MR
Am J Hum Genet; 2019 Dec; 105(6):1112-1125. PubMed ID: 31708117
[TBL] [Abstract][Full Text] [Related]
13. Marked differences in neurochemistry and aggregates despite similar behavioural and neuropathological features of Huntington disease in the full-length BACHD and YAC128 mice.
Pouladi MA; Stanek LM; Xie Y; Franciosi S; Southwell AL; Deng Y; Butland S; Zhang W; Cheng SH; Shihabuddin LS; Hayden MR
Hum Mol Genet; 2012 May; 21(10):2219-32. PubMed ID: 22328089
[TBL] [Abstract][Full Text] [Related]
14. Astrocyte transduction is required for rescue of behavioral phenotypes in the YAC128 mouse model with AAV-RNAi mediated HTT lowering therapeutics.
Stanek LM; Bu J; Shihabuddin LS
Neurobiol Dis; 2019 Sep; 129():29-37. PubMed ID: 31042572
[TBL] [Abstract][Full Text] [Related]
15. Altering cortical input unmasks synaptic phenotypes in the YAC128 cortico-striatal co-culture model of Huntington disease.
Schmidt ME; Buren C; Mackay JP; Cheung D; Dal Cengio L; Raymond LA; Hayden MR
BMC Biol; 2018 Jun; 16(1):58. PubMed ID: 29945611
[TBL] [Abstract][Full Text] [Related]
16. Systemic delivery of mutant huntingtin lowering antisense oligonucleotides to the brain using apolipoprotein A-I nanodisks for Huntington disease.
Caron NS; Aly AE; Findlay Black H; Martin DDO; Schmidt ME; Ko S; Anderson C; Harvey EM; Casal LL; Anderson LM; Rahavi SMR; Reid GSD; Oda MN; Stanimirovic D; Abulrob A; McBride JL; Leavitt BR; Hayden MR
J Control Release; 2024 Mar; 367():27-44. PubMed ID: 38215984
[TBL] [Abstract][Full Text] [Related]
17. In vivo proof-of-concept of removal of the huntingtin caspase cleavage motif-encoding exon 12 approach in the YAC128 mouse model of Huntington's disease.
Casaca-Carreira J; Toonen LJA; Evers MM; Jahanshahi A; van-Roon-Mom WMC; Temel Y
Biomed Pharmacother; 2016 Dec; 84():93-96. PubMed ID: 27639545
[TBL] [Abstract][Full Text] [Related]
18. Selective degeneration in YAC mouse models of Huntington disease.
Van Raamsdonk JM; Warby SC; Hayden MR
Brain Res Bull; 2007 Apr; 72(2-3):124-31. PubMed ID: 17352936
[TBL] [Abstract][Full Text] [Related]
19. Multiple phenotypes in Huntington disease mouse neural stem cells.
Ritch JJ; Valencia A; Alexander J; Sapp E; Gatune L; Sangrey GR; Sinha S; Scherber CM; Zeitlin S; Sadri-Vakili G; Irimia D; Difiglia M; Kegel KB
Mol Cell Neurosci; 2012 May; 50(1):70-81. PubMed ID: 22508027
[TBL] [Abstract][Full Text] [Related]
20. Mutant huntingtin expression in microglia is neither required nor sufficient to cause the Huntington's disease-like phenotype in BACHD mice.
Petkau TL; Hill A; Connolly C; Lu G; Wagner P; Kosior N; Blanco J; Leavitt BR
Hum Mol Genet; 2019 May; 28(10):1661-1670. PubMed ID: 30624705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
